<DOC>
	<DOCNO>NCT00353600</DOCNO>
	<brief_summary>A clinical intervention perform adult diabetic Pima Indians proteinuria determine angiotensin convert enzyme ( ACE ) inhibitor effective slow progression renal disease person overt diabetic nephropathy attributable type 2 diabetes mellitus ( NIDDM ) . The study conduct Gila River Indian Community include proteinuric subject select Diabetic Renal Disease Study ( DRDS ; NIH Protocol Number 88-DK-79 ) glomerular function measure six-monthly interval past 48 month . Twenty-five subject ( 12 men , 13 woman ) age 31-64 year eligible study . These subject urinary albumin-to-creatinine ration &gt; =300 mg/g ( equivalent 300 mg albumin/day ) , serum creatinine concentration &lt; 3.0 mg/dl , evidence nondiabetic renal disease . Their GFR slop average -0.49 ml/min/month ( 95 % confidence interval , -0.91 -0.07 ) , 11 ( 8 men , 3 woman ) hypertensive ( systolic blood pressure &gt; =140 mm Hg , diastolic blood pressure &gt; =90 mm Hg ) . Subjects treat ACE inhibitor , measurement glomerular filtration rate ( GFR ) renal plasma flow ( RPF ) make six monthly interval subject ' progress renal failure . GFR slope ( ml.min/month ) compute , slope prior initiation ACE inhibitor compare obtain treatment .</brief_summary>
	<brief_title>Delaying Progression Diabetic Nephropathy Pima Indians</brief_title>
	<detailed_description>A clinical intervention perform adult diabetic Pima Indians proteinuria determine angiotensin convert enzyme ( ACE ) inhibitor effective slow progression renal disease person overt diabetic nephropathy attributable type 2 diabetes mellitus . The study conduct Gila River Indian Community include proteinuric subject select Diabetic Renal Disease Study ( DRDS ; NIH Protocol Number 88-DK-79 ) glomerular function measure six-monthly interval past 48 month . Twenty-five subject ( 12 men , 13 woman ) age 31-64 year eligible study . These subject urinary albumin-to-creatinine ratio great equal 300 mg/g ( equivalent 300 mg albumin/day ) , serum creatinine concentration less 3.0 mg/dl , evidence nondiabetic renal disease . Their GFR slop average -0.49 ml/min/month ( 95 percent confidence interval , -0.91 -0.07 ) , 11 ( 8 men , 3 woman ) hypertensive ( systolic blood pressure great equal 140 mm Hg , diastolic blood pressure great equal 90 mm Hg ) . Subjects treat ACE inhibitor , measurement glomerular filtration rate ( GFR ) renal plasma flow ( RPF ) make six monthly interval subject ' progress renal failure . GFR slope ( ml/min/month ) compute , slope prior initiation ACE inhibitor compare obtain treatment .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>INCLUSION CRITERIA : To eligible participation study , subject must meet following criterion : Previous completion DRDS ; Serum creatinine concentration le 3.0 mg/dl ; Serum potassium concentration less equal 5.7 mEq/L ; At least 2 3 screen urinary albumintocreatinine ratio great equal 300 mg/g ; Willingness , receive thorough explanation study , participate . Severe hypertension affect eligibility study . EXCLUSION CRITERIA : In addition criterion outline DRDS protocol , subject follow characteristic exclude : Pregnancy . Women childbearing age surgically sterilize must negative pregnancy test prior entry prior renal clearance study . Hypersensitivity ACE inhibitor . Conditions likely interfere inform consent compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 16, 2011</verification_date>
	<keyword>Proteinuria</keyword>
	<keyword>Renal Failure</keyword>
	<keyword>Angiotension Converting Enzyme Inhibitor</keyword>
	<keyword>Glomerular Filtration Rate</keyword>
</DOC>